Overview
Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical-stage biopharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug - Alpha-1 antitrypsin (AAT).
Our strategy is to advance new therapies for AAT that we believe have the potential to move through clinical trials quickly, shepherd them through the FDA approval process and advance them through to commercialization.
We intend to leverage clinical trials and sponsored research agreements with collaborations with existing AAT manufacturers for the development and commercialization of AAT in additional indications that potentially could exceed AAT's current estimated market of $400 million.
We plan to collaborate with companies that have the infrastructure,
expertise and large scale marketing capability to properly handle
late-stage clinical development and commercialization.
License Agreements
Omni Bio is the licensee of patent portfolios from the University of Colorado and a privately-held company that include 3 issued patents and 24 patent applications.The patent portfolios are comprised of new methods of use for AAT in the areas of diabetes, cellular transplantation, which includes islet transplantation and the treatment of bone marrow transplantation disease, and certain bacterial and viral disorders.
Omni Bio currently owns a 25% equity interest in a newly formed private company, BioMimetix Pharmaceutical, Inc. BioMimetix is the exclusive licensee to a patent held by Duke University and was formed to develop a new class of patented compounds for the treatment of various disease and health care treatment classifications including radiation toxicity incurred during the treatment of cancer.
Investment Highlights
- Broad intellectual property position for new AAT therapies
- Type 1 diabetes
- Bone marrow transplantation disease
- Islet cell transplantation
- Influenza and HIV
- Bacterial disorders and anthrax exposure
- 3 issued patents and 24 patent applications
- Currently conducting AAT human clinical trial in Type 1 diabetes
- FDA approved pharmaceutical applied to new markets
- Outsourced business model requiring low overhead
- Capital requirements primarily focused on clinical trial, sponsored research and patent prosecution
- Omni Bio is also a significant equity investor in a company with a potential new drug for the treatment of radiation toxicity
Press Releases & CORPORATE COMMUNICATIONS
Omni Bio to Present at Investor Conference
09-Jan-2012 - Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets Eighth Annual Equity Conference on January 18. 2012
22-Dec-2011 - Diabetes :Patent Issuance - Bio Holding Licensing Arrangement
08-Dec-2011 - Patent Issued for Treatment of Diabetes
Omni Bio Investment in BioMimetix Pharmaceutical
21-Jul-2011 - Omni Bio Acquires 25% Interest in BioMimetix Pharmaceutical
Shareholder Letter - March 2011
31-Mar-2011 - CEO Letter to Shareholders
Clinical Trials - Expansion and New Indications
28-Feb-2011 - Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients; Receives Letters of Intent for New Human Trials Expanding Testing of AAT in Transplantation, Graft vs. Host Disease, Late Stage Type 1 Diabetes and Type 2 Diabetes
Investor and Business Operations Update
28-Feb-2011 - Omni provides investor and business operations update - February 28, 2011
24-Feb-2011 - Omni Bio Pharmaceutical Realigns Management; Appoints Dr. James Crapo as CEO; Dr. Charles Dinarello as Chief Scientific Officer and Chief Medical Director
Biotech Showcase Investor Presentation
11-Jan-2011 - Investor Presentation at 2011 Biotech Showcase.
Patent for Preventing Anthrax Infection
04-Jan-2011 - Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection; Patent Covers a Novel Approach for Preventing Bacterial Infection, including Anthrax; Management to Discuss Progress at Biotech Showcase 2011
Patent for Treating and Preventing Viral Infection
23-Nov-2010 - Omni Bio Awarded Patent for Treating and Preventing Viral Infection
First Infusion in Phase I/II Clinical Trial of Alpha-1 Antitrypsin
18-Oct-2010 - Omni Bio Announces First Infusion in Phase I/II Clinical Trial of Alpha 1 Antitrypsin in Recently Diagnosed Diabetic Patients; Treatment Commences at Barbara Davis Center for Childhood Diabetes at University of Colorado Denver Anschutz Medical Campus
New Multi-Year Research Agreement With University of Colorado
24-Aug-2010 - New Multi-Year Research Agreement With University of Colorado Denver; Potential to Support Human Clinical Trial of Alpha-1 Antitrypsin (AAT) in Influenza; Dr. Charles A. Dinarello Co-Awarded Novartis Prize at XIV International Congress of Immunology
FDA Clearance for Alpha-1 antitrypsin Type 1 Diabetes Clinical Trial-Screening
08-Jun-2010 - Omni Bio Announces FDA IND Clearance for Alpha-1 antitrypsin (AAT) Type 1 Diabetes Clinical Trial; Screening Underway at Barbara Davis Center for Childhood Diabetes at University of Colorado Denver Anschutz Medical Campus; Management to Present at Jefferies 2010 Global Life Sciences Conference
Panel on Alpha-1-Antitrypsin at 8th World Congress
11-Mar-2010 - Omni Bio Pharmaceutical, Inc. Hosts Panel on Alpha-1-Antitrypsin ("AAT") at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
Fall 2009 Micro Cap/Small Cap Confrence
22-Sep-2009 - Omni Bio Pharmaceutical to Present at Accredited Members Fall 2009 Micro Cap/Small Cap Conference
20-Jul-2009 - Omni Bio Pharmaceutical Announces Ticker Symbol Change to OMBP
24-Jun-2009 - Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
Name Change and Managerial Appointments
02-Jun-2009 - Omni Bio Pharmaceutical, Inc. Completes Name Change and Announces Managerial Appointments and Position Changes
Dr. Dinarello Co-Awarded Largest US Prize in Medical Research
29-Apr-2009 - Dr. Charles A. Dinarello Co-Awarded Largest US Prize in Medical Research, the Albany Medical Center Prize in Medicine and Biomedical Research
Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets’ Eighth Annual Equity Conferen
19-Jan-2012 -
